FDA takes action against the use of OTC benzocaine teething products due to serious safety risk, lack of benefit - FDA Press Releases

OTC oral health products containing benzocaine for the temporary relief of sore gums due to teething in infants or children should no longer be marketed. FDA is asking companies to stop selling these products for such use and requesting that companies add new warnings to all other benzocaine oral health products to describe certain serious risks.

from Food and Drug Administration--Press Releases https://ift.tt/2J11k4c
via IFTTT